{"filing":{"accession_number":"0001213900-26-068495","cik":"0001611747","ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ea0294725-6k_scinai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390026068495/ea0294725-6k_scinai.htm"},"events":[{"id":12249,"run_id":10813,"accession_number":"0001213900-26-068495","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release dated June 10, 2026, disclosing Scinai's first-quarter 2026 financial results (three months ended March 31, 2026), including revenues, operating loss, net income, and balance-sheet metrics. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, cash flows, and changes in shareholders' equity) and a corporate update. While the release also discusses the Recipharm Israel acquisition and strategic initiatives, the primary disclosure is the quarterly financial results, which is characteristic of an earnings_release. The acquisition is presented as a completed transaction within the results narrative rather than as a discrete M\u0026A event announcement.","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9052,"accession_number":"0001213900-26-068495","item_number":"EX-99.1","item_title":"ea029472501ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated June 10, 2026, disclosing Scinai's first-quarter 2026 financial results (three months ended March 31, 2026), including revenues, operating loss, net income, and balance-sheet metrics. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, cash flows, and changes in shareholders' equity) and a corporate update. While the release also discusses the Recipharm Israel acquisition and strategic initiatives, the primary disclosure is the quarterly financial results, which is characteristic of an earnings_release. The acquisition is presented as a completed transaction within the results narrative rather than as a discrete M\u0026A event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:30:54.680529+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9052,"accession_number":"0001213900-26-068495","item_number":"EX-99.1","item_title":"ea029472501ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated June 10, 2026, disclosing Scinai's first-quarter 2026 financial results (three months ended March 31, 2026), including revenues, operating loss, net income, and balance-sheet metrics. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, cash flows, and changes in shareholders' equity) and a corporate update. While the release also discusses the Recipharm Israel acquisition and strategic initiatives, the primary disclosure is the quarterly financial results, which is characteristic of an earnings_release. The acquisition is presented as a completed transaction within the results narrative rather than as a discrete M\u0026A event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:30:54.680529+00:00","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-06-15"}]}